Literature DB >> 20473213

Privacy-maintaining propensity score-based pooling of multiple databases applied to a study of biologics.

Jeremy A Rassen1, Daniel H Solomon, Jeffrey R Curtis, Lisa Herrinton, Sebastian Schneeweiss.   

Abstract

INTRODUCTION: A large study on the safety of biologics required pooling of data from multiple data sources, but while extensive confounder adjustment was necessary, private, individual-level covariate information could not be shared.
OBJECTIVES: To describe the methods of pooling data that investigators considered, and to detail the strengths and limitations of the chosen method: a propensity score (PS)-based approach that allowed for full multivariate adjustment without compromising patient privacy. RESEARCH
DESIGN: The project had a central data coordinating center responsible for collection and analysis of data. Private data could not be transmitted to the data coordinating center. Investigators assessed 4 methods for pooled analyses: full covariate sharing, cell-aggregated sharing, meta-analysis, and the PS-based method. We evaluated each method for protection of private information, analytic integrity and flexibility, and ability to meet the study's operational and statistical needs.
RESULTS: Analysis of 4 example datasets yielded substantially similar estimates if data were pooled with a PS versus individual covariates (0%-3% difference in point estimates). Several practical challenges arose. (1) PSs are best suited for dichotomous exposures but 6 or more exposure categories were desired; we chose a series of exposure contrasts with a common referent group. (2) Subgroup analyses had to be specified a priori. (3) Time-varying exposures and confounders required appropriate analytic handling including re-estimation of PSs. (4) Detection of heterogeneity among centers was necessary.
CONCLUSIONS: The PS-based pooling method offered strong protection of patient privacy and a reasonable balance between analytic integrity and flexibility of study execution. We would recommend its use in other studies that require pooling of databases, multivariate adjustment, and privacy protection.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20473213      PMCID: PMC2933455          DOI: 10.1097/MLR.0b013e3181d59541

Source DB:  PubMed          Journal:  Med Care        ISSN: 0025-7079            Impact factor:   2.983


  17 in total

1.  Estimating exposure effects by modelling the expectation of exposure conditional on confounders.

Authors:  J M Robins; S D Mark; W K Newey
Journal:  Biometrics       Date:  1992-06       Impact factor: 2.571

2.  Methods for pooling results of epidemiologic studies: the Pooling Project of Prospective Studies of Diet and Cancer.

Authors:  Stephanie A Smith-Warner; Donna Spiegelman; John Ritz; Demetrius Albanes; W Lawrence Beeson; Leslie Bernstein; Franco Berrino; Piet A van den Brandt; Julie E Buring; Eunyoung Cho; Graham A Colditz; Aaron R Folsom; Jo L Freudenheim; Edward Giovannucci; R Alexandra Goldbohm; Saxon Graham; Lisa Harnack; Pamela L Horn-Ross; Vittorio Krogh; Michael F Leitzmann; Marjorie L McCullough; Anthony B Miller; Carmen Rodriguez; Thomas E Rohan; Arthur Schatzkin; Roy Shore; Mikko Virtanen; Walter C Willett; Alicja Wolk; Anne Zeleniuch-Jacquotte; Shumin M Zhang; David J Hunter
Journal:  Am J Epidemiol       Date:  2006-04-19       Impact factor: 4.897

3.  American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis.

Authors:  Kenneth G Saag; Gim Gee Teng; Nivedita M Patkar; Jeremy Anuntiyo; Catherine Finney; Jeffrey R Curtis; Harold E Paulus; Amy Mudano; Maria Pisu; Mary Elkins-Melton; Ryan Outman; Jeroan J Allison; Maria Suarez Almazor; S Louis Bridges; W Winn Chatham; Marc Hochberg; Catherine MacLean; Ted Mikuls; Larry W Moreland; James O'Dell; Anthony M Turkiewicz; Daniel E Furst
Journal:  Arthritis Rheum       Date:  2008-06-15

Review 4.  Estimating causal effects from large data sets using propensity scores.

Authors:  D B Rubin
Journal:  Ann Intern Med       Date:  1997-10-15       Impact factor: 25.391

5.  Meta-analysis in clinical trials.

Authors:  R DerSimonian; N Laird
Journal:  Control Clin Trials       Date:  1986-09

6.  A population-based study of the drug interaction between proton pump inhibitors and clopidogrel.

Authors:  David N Juurlink; Tara Gomes; Dennis T Ko; Paul E Szmitko; Peter C Austin; Jack V Tu; David A Henry; Alex Kopp; Muhammad M Mamdani
Journal:  CMAJ       Date:  2009-01-28       Impact factor: 8.262

7.  Confounder summary scores when comparing the effects of multiple drug exposures.

Authors:  Suzanne M Cadarette; Joshua J Gagne; Daniel H Solomon; Jeffrey N Katz; Til Stürmer
Journal:  Pharmacoepidemiol Drug Saf       Date:  2010-01       Impact factor: 2.890

8.  High-dimensional propensity score adjustment in studies of treatment effects using health care claims data.

Authors:  Sebastian Schneeweiss; Jeremy A Rassen; Robert J Glynn; Jerry Avorn; Helen Mogun; M Alan Brookhart
Journal:  Epidemiology       Date:  2009-07       Impact factor: 4.822

9.  Evaluating medication effects outside of clinical trials: new-user designs.

Authors:  Wayne A Ray
Journal:  Am J Epidemiol       Date:  2003-11-01       Impact factor: 4.897

10.  Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome.

Authors:  P Michael Ho; Thomas M Maddox; Li Wang; Stephan D Fihn; Robert L Jesse; Eric D Peterson; John S Rumsfeld
Journal:  JAMA       Date:  2009-03-04       Impact factor: 56.272

View more
  16 in total

1.  Initiation of tumor necrosis factor-α antagonists and the risk of hospitalization for infection in patients with autoimmune diseases.

Authors:  Carlos G Grijalva; Lang Chen; Elizabeth Delzell; John W Baddley; Timothy Beukelman; Kevin L Winthrop; Marie R Griffin; Lisa J Herrinton; Liyan Liu; Rita Ouellet-Hellstrom; Nivedita M Patkar; Daniel H Solomon; James D Lewis; Fenglong Xie; Kenneth G Saag; Jeffrey R Curtis
Journal:  JAMA       Date:  2011-11-06       Impact factor: 56.272

2.  Collaborative, pooled and harmonized study designs for epidemiologic research: challenges and opportunities.

Authors:  Catherine R Lesko; Lisa P Jacobson; Keri N Althoff; Alison G Abraham; Stephen J Gange; Richard D Moore; Sharada Modur; Bryan Lau
Journal:  Int J Epidemiol       Date:  2018-04-01       Impact factor: 7.196

3.  Study design for a comprehensive assessment of biologic safety using multiple healthcare data systems.

Authors:  Lisa J Herrinton; Jeffrey R Curtis; Lang Chen; Liyan Liu; Elizabeth Delzell; James D Lewis; Daniel H Solomon; Marie R Griffin; Rita Ouellet-Hellstom; Timothy Beukelman; Carlos G Grijalva; Kevin Haynes; Bindee Kuriya; Joyce Lii; Ed Mitchel; Nivedita Patkar; Jeremy Rassen; Kevin L Winthrop; Parivash Nourjah; Kenneth G Saag
Journal:  Pharmacoepidemiol Drug Saf       Date:  2011-09-15       Impact factor: 2.890

4.  Cardiovascular risk in rheumatoid arthritis: comparing TNF-α blockade with nonbiologic DMARDs.

Authors:  Daniel H Solomon; Jeffrey R Curtis; Kenneth G Saag; Joyce Lii; Lang Chen; Leslie R Harrold; Lisa J Herrinton; David J Graham; Mary K Kowal; Bindee Kuriya; Liyan Liu; Marie R Griffin; James D Lewis; Jeremy A Rassen
Journal:  Am J Med       Date:  2013-08       Impact factor: 4.965

5.  A modular, prospective, semi-automated drug safety monitoring system for use in a distributed data environment.

Authors:  Joshua J Gagne; Shirley V Wang; Jeremy A Rassen; Sebastian Schneeweiss
Journal:  Pharmacoepidemiol Drug Saf       Date:  2014-04-30       Impact factor: 2.890

6.  Conducting Privacy-Preserving Multivariable Propensity Score Analysis When Patient Covariate Information Is Stored in Separate Locations.

Authors:  Justin Bohn; Wesley Eddings; Sebastian Schneeweiss
Journal:  Am J Epidemiol       Date:  2017-03-15       Impact factor: 4.897

7.  Association between anti-TNF-α therapy and all-cause mortality.

Authors:  Lisa J Herrinton; Liyan Liu; Lang Chen; Leslie R Harrold; Marsha A Raebel; Jeffrey R Curtis; Marie R Griffin; Daniel H Solomon; Kenneth G Saag; James D Lewis
Journal:  Pharmacoepidemiol Drug Saf       Date:  2012-10-15       Impact factor: 2.890

8.  Association between anti-TNF-α therapy and interstitial lung disease.

Authors:  Lisa J Herrinton; Leslie R Harrold; Liyan Liu; Marsha A Raebel; Ananse' Taharka; Kevin L Winthrop; Daniel H Solomon; Jeffrey R Curtis; James D Lewis; Kenneth G Saag
Journal:  Pharmacoepidemiol Drug Saf       Date:  2013-01-29       Impact factor: 2.890

Review 9.  Analytic and Data Sharing Options in Real-World Multidatabase Studies of Comparative Effectiveness and Safety of Medical Products.

Authors:  Sengwee Toh
Journal:  Clin Pharmacol Ther       Date:  2020-01-24       Impact factor: 6.875

10.  Comparison of privacy-protecting analytic and data-sharing methods: A simulation study.

Authors:  Kazuki Yoshida; Susan Gruber; Bruce H Fireman; Sengwee Toh
Journal:  Pharmacoepidemiol Drug Saf       Date:  2018-07-18       Impact factor: 2.890

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.